Drug intelligence / Profile preview

177Lu-DOTA-zolbetuximab

Development stage: Preclinical
Lead developer: Massachusetts General Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-DOTA-zolbetuximab is a claudin 18.2-targeted radiopharmaceutical therapy designed for the treatment of gastric and pancreatic cancers. It consists of the monoclonal antibody zolbetuximab, which specifically binds to claudin 18.2 (CLDN18.2), conjugated via a DOTA chelator to the beta-emitting radioisotope lutetium-177 (177Lu). This agent delivers targeted radiation directly to tumor cells expressing CLDN18.2, a biomarker frequently overexpressed in upper gastrointestinal malignancies. Preclinical studies have demonstrated significant tumor regression and complete eradication in some models without observed radiation-induced toxicity.

Other names: Lutetium (177Lu) DOTA-zolbetuximab

Targets

Claudin 18.2

Beyond the preview

Go deeper on 177Lu-DOTA-zolbetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-DOTA-zolbetuximab.